Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Monday

Xeris Biopharma (NASDAQ:XERS) will likely be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $86.00 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Xeris Biopharma Stock Down 1.8%

XERS opened at $6.61 on Monday. The stock has a market cap of $1.10 billion, a P/E ratio of -66.09 and a beta of 0.52. Xeris Biopharma has a 12 month low of $3.58 and a 12 month high of $10.08. The company has a fifty day simple moving average of $7.28 and a 200 day simple moving average of $7.66.

Analyst Ratings Changes

Several equities research analysts have issued reports on XERS shares. Barclays started coverage on Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Piper Sandler lifted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.08.

Insider Activity at Xeris Biopharma

In other news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total value of $120,000.00. Following the sale, the insider directly owned 1,685,426 shares in the company, valued at $13,483,408. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Johnson sold 135,400 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director owned 698,083 shares of the company’s stock, valued at $5,040,159.26. The trade was a 16.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 240,308 shares of company stock worth $1,745,120. 4.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the last quarter. State Street Corp raised its stake in shares of Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.